Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib.

Emma Sampson Erhan Kavakbasi Natalie T Mills Hikaru Hori Klaus Oliver Schubert Célia Fourrier Bernhard T Baune

Published in: The international journal of neuropsychopharmacology (2024)

This analysis suggests favorable effects of vortioxetine on emotional blunting in both short- and long-term course. The beneficial impact of vortioxetine on emotional blunting was weaker in celecoxib-augmented patients compared with placebo, possibly due to pharmacokinetic interactions. Clinical Trials Registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000527369p. Registered on 11 April 2017, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000527369p.

Keyphrases

clinical trial
phase iii
major depressive disorder
phase ii
double blind
study protocol
open label
end stage renal disease
newly diagnosed
ejection fraction
oxidative stress
chronic kidney disease
bipolar disorder
prognostic factors
depressive symptoms
quantum dots
virtual reality